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patients, and 1.4% for blacks (P .0002). There was a longer operating time
(P  .001) and total length of stay (P  .001), more postoperative
pneumonias (P  .0049), unplanned intubations (P  .001), ventilator
dependence (P  .001), cardiac arrests (P  .001), bleeding requiring
transfusions (P  .0024), and returns to the operating room (P  .0021)
among black patients. Multivariate logistic regression identified black race as an
independent risk factor for 30-day mortality (relative risk, 1.9;P .0007). Black
patients also had more in-hospital deaths than white patients (73.7% vs 43.1%,
P .001). The rate of postdischarge strokes did not differ between the groups:
36.4% of all strokes occurred after discharge at a mean of 8.3 days and 54.3% of
deaths occurred after discharge at a mean of 11 days.
Conclusions: Black race is identified as an independent risk factor for
30-day mortality after CEA. A significant proportion of strokes and deaths
occur after discharge in both racial groups evaluated.
Progression of Asymptomatic Carotid Stenosis Despite Optimal Med-
ical Therapy
Valy Boulom, Mark Conrad, Shankha Mukhopadhyay, Virendra Patel, Ashu
Garg, Karen Furie, Richard Cambria. Massachusetts General Hospital,
Boston, Mass
Introduction and objectives: Despite level 1 evidence in support of
carotid endarterectomy (CEA) vs medical therapy in selected asymptomatic
patients, an alternative posture is that optimal medical therapy (OMT) has
not been adequately studied and that such OMT has reduced stroke risk to
levels wherein CEA is no longer justified. The goal of this study was to
determine the natural history of patients with asymptomatic moderate
(50%-69%) carotid stenosis (AMCS) in a contemporary cohort as a function
of their associated medical therapy.
Methods: Patients with AMCS determined by duplex ultrasound
(DUS) imaging from 2005 to 2006 were identified in our hospital database.
Patients were included in the cohort if they had at least one additional DUS
during the 6-year follow-up interval. Patient characteristics, including med-
ication history and lipid levels, were collected. Patients were considered to
have OMT if they were on aspirin and a statin with a low-density lipoprotein
(LDL) level100 mg/dL. Study end points included progression of carotid
disease by DUS (70%-100%), development of ipsilateral neurologic symp-
toms (stroke/transient ischemic attack), and death.
Results: There were 906 carotids in 801 patients in the study cohort.
The average age was 72.5 years, 77.3% had hypertension, 59.7% had
coronary artery disease (CAD), and 84% were on a statin. The LDL choles-
terol level was always normal (100) in 56.4%, and 29.4% had OMT. The
5-year actuarial outcomes are detailed in the Table. Ipsilateral symptoms
developed in 97 patients during follow-up (58% of these were strokes).
Multivariate predictors of disease progression were chronic kidney disease
(hazard ratio [HR], 2.14; confidence interval [CI], 1.22-3.76; P  .0008),
and statin use (HR, 1.59; CI, 1.0-2.53; P .0049). The multivariate models
of symptom development and survival showed that statin use was protective
for both (symptoms: HR, .046; CI, .026-0.79; P  .0005; survival: HR,
.050; CI, .034-0.73; P  .00004).
Conclusions: OMT failed to prevent disease progression or develop-











Survival 75.4 75.4 75.4 .86
Freedom from disease
progression 61.5 60.6 61.7 .37
Freedom from symptoms 87 85 87.9 .17
Freedom from ipsilateral
CEA/CAS 71.7 67.5 73.6 .10
Outcomes of Endovascular Interventions for Salvage of Renal Trans-
plant Allografts
Shipra Arya, Dawn M. Coleman, Nicholas Osborne, Peter K. Henke, John
E. Rectenwald, Michael Englesbe, Katherine A. Gallagher. University of
Michigan, Ann Arbor, Mich
Introduction and objectives: As renal transplantation has been per-
formed with increased frequency, interventions to preserve graft function and
integrity have been steadily increasing. This study examines the outcomes of
endovascular therapy based on indication for renal allograft salvage.
Methods: A prospective transplant registry was queried for all patients
undergoing endovascular interventions for transplant allograft salvage from
2002 to 2011. Demographics, perioperative data, and transplant function
outcomes were extracted and analyzed.
Results: Among 34 renal transplant recipients who underwent endo-
vascular interventions for graft salvage, the mean age was 48.2 years (18-74
years), and 62% were men. The indications for intervention included wors-
ening serum creatinine (n  15), renovascular hypertension (n  11), and
structural abnormalities identified on noninvasive imaging (n 8). Translu-
minal angioplasty, with or without stenting, was done in 26 patients: 14
(41.2%) with significant transplant stenosis, 11 (32.4%) with peripheral
arterial disease (PAD) in proximal iliac vessels, and one with iliac dissection.
Five arteriovenous fistulae and two pseudoaneurysms required emboliza-
tion. One patient had deep venous thrombosis causing obstruction of
allograft outflow requiring lysis. There were no periprocedural deaths, and
30-day morbidity was 17.6%. Of patients with worsening renal function,
67% had improvement or stabilization of their renal function. Interestingly,
only 36% of patients with renovascular hypertension showed improvement.
Mean follow-up was 4.2 years. There were no significant differences in
transplant allograft survival over the duration of follow-up based on indica-
tion for endovascular intervention (Fig; log-rank test, P  .03).
Conclusions: Endovascular salvage of renal allograft transplants can be
safely done for various indications, although patients with renovascular
hypertension were less likely to improve. Despite differences in symptomatic
outcome, the indication for initial intervention does not significantly influ-
ence the long-term transplant graft survival.
Clinical Effectiveness of Secondary Interventions for Restenosis Fol-
lowing Renal Artery Angioplasty and Stenting: Does it Help, Hurt or
Even Make a Difference?
Benjamin S. Brooke, Samuel T. Simone, Philip P. Goodney, Randall R.
DeMartino, Daniel B. Walsh, David H. Stone, Richard J. Powell, Jack L.
Cronenwett, Brian W. Nolan. Dartmouth-Hitchcock Medical Center, Leb-
anon, NH
Introduction and objectives: Secondary interventions for restenosis
after renal artery angioplasty and stenting are commonly performed, despite
limited data on their effectiveness. This study was designed to evaluate
whether successful outcomes are achieved in patients after endovascular
treatment of recurrent renal artery stenosis (RAS).
Methods: We conducted a retrospective review of all patients who
underwent renal artery angioplasty or stenting, or both, for renovascular
hypertension between 2001 and 2011 at Dartmouth-Hitchcock Medical
Center. We compared the clinical effectiveness of secondary vs primary
interventions. Nonparametric models were used to identify factors associ-
ated with successful outcomes, as measured by changes in blood pressure,
estimated glomerular filtration rate (eGFR), and number of antihypertensive
medications.
Results: Thirty-nine patients (54 renal arteries) underwent secondary
interventions for recurrent RAS, and 180 patients (180 arteries) underwent
primary intervention. There were no significant differences between patients
undergoing primary vs secondary interventions with respect to preoperative
medication usage (including antihypertensive, antiplatelet or statin medica-
tions), comorbid conditions, or blood pressure. Primary and secondary
interventions were both completed using a similar proportion of bare-metal
stents (90%), with no difference in procedural complications or technical
success. At a mean follow-up of 23 months (range, 1-128 months), similar
improvements in renal function were found between patients undergoing
primary and secondary interventions (Fig). There were no differences in
number of antihypertensive medications, overall blood pressure manage-
ment, or overall survival.
Fig.
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Conclusions: Patients undergoing secondary interventions for recur-
rent RAS have comparable outcomes as those for primary interventions.
These data suggest that repeated endovascular procedures for renal artery
restenosis can be safely undertaken while maintaining similar expectations
for clinical improvement.
Comparing Computed Tomographic Angiography vs Ultrasound Vein
Mapping in Evaluating the Suitability of the Great Saphenous Vein for
Distal Bypass
Omar P. Haqqani, Benjamin W. Botsford, Prakhar K. Agarwal, Mark D.
Iafrati, William C. Mackey, James M. Estes. Tufts University Medical
Center, Boston, Mass
Introduction and objectives: Although computed tomography an-
giography (CTA) is commonly used preoperatively to determine arterial anat-
omy, duplex ultrasound (DUS) vein mapping is frequently used to determine
the suitability of bypass conduits. The purpose of this study was to determine the
correlation between DUS and CTA in the evaluation of the great saphenous
vein (GSV) with respect to diameter and usability in lower extremity bypasses.
Methods: A single-center retrospective review identified patients who
had both CTA and DUS in preparation for lower extremity bypass, between
June 2001 and February 2012. DUS reports included GSV diameter at the
saphenofemoral junction, midthigh, knee, and midcalf. CTAs were reviewed
independently by two vascular surgeons who were blinded to the DUS and
surgical findings. The interobserver variability was analyzed using Pearson
correlation. The relationship between CTA and DUS measurements was
compared at each anatomic level using correlation coefficients. The predic-
tive ability of CTA was analyzed using the Fisher exact test.
Results: Sixteen patients (9 men [56.3%]) underwent CTA and DU in
preparation for lower extremity bypass (23 limbs). The average patient age
was 65.1 years, 10 (62.5%) were diabetic, and three (18.8%) had a history of
DVT or phlebitis. A high degree of correlation existed between the two
surgeons’ GSV measurements using CTA (r  .09996, P  .0001), and a
strong correlation existed between CTA and DUS GSV measurements (r
.07306, P .0001). CTA assessment of GSV usability correlates with actual
usage as conduit (P .0099) with a sensitivity of 92% and sensitivity of 80%.
Conclusions:CTA can be accurately used to evaluate the diameter and
usability of the GSV for lower extremity revascularization, eliminating the
need for additional testing.
Impact of Severe Chronic Kidney Disease on Outcomes of Endovascu-
lar Intervention for Infrainguinal Peripheral Arterial Disease
Virendra I. Patel, Shankha Mukhopadhyay, Julie M. Guest, Mark F. Conrad,
Glenn M. LaMuraglia, Christopher J. Kwolek, Richard P. Cambria. Mas-
sachusetts General Hospital, Boston, Mass
Introduction and objectives: Patients with class 4 and 5 chronic kidney
disease (CKD) and peripheral vascular disease (PVD) are at increased risk of
major adverse limb events (MALE), amputation, and death. We evaluated the
effect of CKD on outcomes after peripheral vascular intervention (PVI).
Methods: All primary PVIs performed at a single institution (January
2002-December 2009) were included. End points were defined by Society
for Vascular Surgery (SVS) objective performance goals for critical limb
ischemia (J Vasc Surg 2009;50:1462-73): death, reintervention, amputa-
tion, death/amputation, and MALE (reintervention or amputation).
Results: A total of 879 PVIs were performed, with CKD in 125
(14%). CKD patients were significantly (P  .05) more likely to have
diabetes (64% vs 46%), critical ischemia (72% vs 11%), multilevel PVI
(34% vs 19%), and tibial intervention (35% vs 20%). Distribution of
Trans-Atlantic Inter-Society Consensus C and D lesions were similar
(19% CKD vs 15%; P  .02). CKD was not associated with SVS high-risk
criteria (age 80 years and CLI; 14% CKD vs 11%; P  .3). CKD
predicted 30-day reintervention (odds ratio [OR], 2.3; confidence inter-
val [CI], 1.5-4; P  .005), amputation/death (OR, 3.1; CI, 1.1-9; P 
.004), and MALE (OR, 2.8; CI, 1.3-6.1; P  .004) independent of CLI.
On Cox regression, CKD increased late death (HR, 2.4; CI, 1.8-3.2; P
.01), amputation (HR, 2.1; CI, 1.1-3.9; P  .002), and death/amputa-
tion (HR, 1.8; CI, 1.3-2.4; P  .004), with no increase in reintervention
or MALE. On Kaplan-Meier analysis, CKD was significantly (log-rank,
P  .05) associated with death (31%  4% vs 7%  1%), amputation
(14%  3% vs 3%  1%), death/amputation (31%  4% vs 9%  1%), and
MALE (40%  5% vs 26%  2%) at 1 year. Freedom from reintervention
was similar at 1 year (70%  5% severe CKD vs 75%  2%; P  .23).
Conclusions: Current performance goals have excluded patients with
severe CKD, yet CKD independently predicts early and late adverse events
after PVI, in particular, excessive mortality. CKD should figure prominently
in clinical decision making for patients with PVD.
Long-Term Durability of Endovascular and Open Revascularization
for Disabling Claudication
Hasan H. Dosluoglu,1 Purandath Lall,1 Linda M. Harris,2 Maciej L.
Dryjski2. 1VA Western NY HCS, SUNY at Buffalo, Buffalo, NY; 2SUNY at
Buffalo, Buffalo, NY
Introduction and objectives: To compare clinical outcomes and
long-term durability of aortoiliac (AI) and femoropopliteal (FP) endovascu-
lar (EV) and open interventions for disabling claudication (DC), and to
determine the effect of Trans-Atlantic Inter-Society Consensus (TASC
classification (A/B vs C/D) on outcomes.
Methods: Patients with Rutherford 3 DC, who had open (n 
93,107 limbs), or EV interventions (n  167, 206 limbs) between June
2001 and December 2009 were grouped as AI open (n  47), AI
EV-A/B (n 91), AI EV-C/D (n 35), FP open (n 60), FP EV-A/B
(n  29), and FP EV-C/D (n  51). Patency, sustained clinical success
(clinical improvement, freedom from target extremity revascularization),
and secondary clinical success (with target extremity revascularization)
were calculated.
Results: There were more smokers (79% vs 57%, P  .001) and less
diabetes mellitus (25% vs 37%, P  .003) in open and less CAD in FP
EV-A/B (24% vs 50%, P  .0009). Mean follow-up was 48  24 months.
Patency and clinical success rates were similar in iliac subgroups (Table). FP
EV-C/D and FP open groups fared significantly worse than FP EV-A/B. In AI,
9% in open and 15% in EV groups had reinterventions; 1% (n  2) needed
bypass. In FP EV-A/B, 17% needed reinterventions, 3% had bypass; in FPFig.
Fig.
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